永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

未开盘 01-08 16:08:08

2.770

-0.010

-0.36%

最高2.800	最低2.740	成交量20.82万
今开2.800	昨收2.780	日振幅2.16%
总市值17.12亿	流通市值17.12亿	总股本6.18亿
成交额57.45万	换手率0.03%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.77,"timestamp":1767859688164,"preClose":2.78,"halted":0,"volume":208200,"delay":0,"floatShares":618000000,"shares":618000000,"eps":-0.4053155168775714,"marketStatus":"未开盘","change":-0.01,"latestTime":"01-08 16:08:08","open":2.8,"high":2.8,"low":2.74,"amount":574468,"amplitude":0.021583,"askPrice":2.84,"askSize":30000,"bidPrice":2.77,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.4846559436635083,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767922200000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.78,"openAndCloseTimeList":[[1767835800000,1767844800000],[1767848400000,1767859200000]],"volumeRatio":0.243539,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2601363983","title":"绿叶制药(02186)：1类创新药若欣林®用于治疗广泛性焦虑障碍的新适应症中国上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363983","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601363983?lang=zh_cn&edition=full","pubTime":"2026-01-08 19:03","pubTimestamp":1767870230,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，中国国家药品监督管理局药品审评中心已正式受理本集团1类创新药若欣林的新适应症上市申请，拟用于治疗广泛性焦虑障碍。这是该产品自2022年11月获批上市用于治疗抑郁症后的又一里程碑。该研究纳入555例患者，以汉密尔顿焦虑量表总分较基线变化为主要终点，评估若欣林治疗广泛性焦虑障碍的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","06978","159992","BK1574","BK1583","BK1606","02186"],"gpt_icon":0},{"id":"2601949398","title":"创新药“华山奖”企业奖36家入围名单公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2601949398","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601949398?lang=zh_cn&edition=full","pubTime":"2026-01-08 18:19","pubTimestamp":1767867540,"startTime":"0","endTime":"0","summary":"“医学界”与“同写意”共同发起的创新药“华山奖”企业奖入围名单公布，共36家企业入围。奖项旨在发现中国创新药价值医疗标杆，通过量化指标评选产生。奖项分三类：最佳领导型创新医药企业奖，要求企业具有卓越综合实力、深远行业影响力等，年药品销售收入在100亿元以上，百济神州、阿斯利康等12家企业入围；最佳成长型创新医药企业奖，要求企业展现出卓越成长潜力，年药品销售收入处于10亿-100亿元之间，信达生物、传奇生物等12家企业入围；最佳潜力型创新医药企业奖，要求企业展现出卓越创新能力，年药品销售收入在10亿元以下或未有商业化产品，和铂医药、科伦博泰生等2家企业（名单未完全列举）入围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108184317a4abbfff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108184317a4abbfff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","02142","06978","BK1161"],"gpt_icon":0},{"id":"2601356555","title":"2026开年已经有3款创新药密集获批上市，来自恒瑞、百济、赛诺菲","url":"https://stock-news.laohu8.com/highlight/detail?id=2601356555","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601356555?lang=zh_cn&edition=full","pubTime":"2026-01-08 13:44","pubTimestamp":1767851095,"startTime":"0","endTime":"0","summary":"2026新年伊始，医药行业便传来阵阵暖意，根据国家药品监督管理局网站消息，2026开年已经有三款创新药获批上市，其中包含2个国产创新药，分别来自恒瑞医药、百济神州；1个进口产品，来自赛诺菲。业内表示，本次普乐司兰钠注射液的获批，回应了临床在甘油三酯管理方面的迫切患者需求。开年三款创新药的密集获批，离不开国家利好政策的支持。回顾刚刚过去的2025年，我国有76个创新药获批上市，与2024年48个相比，大幅增长58.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108134829a4aaa790&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108134829a4aaa790&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1251922891.USD","LU2328871848.SGD","BK1161","06160","LU1770034418.SGD","LU1969619763.USD","LU0588546209.SGD","BK1574","BK1588","LU1303224171.USD","LU1719994722.HKD","BK1500","06978","BK1583","LU0307460666.USD"],"gpt_icon":0},{"id":"2601351333","title":"交易总额突破1300亿美元！2025年全球创新药BD交易全景分析及趋势预判","url":"https://stock-news.laohu8.com/highlight/detail?id=2601351333","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601351333?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:55","pubTimestamp":1767837325,"startTime":"0","endTime":"0","summary":"本文将基于药渡咨询的深度调研数据，对2025年全球及中国创新药BD交易的全景进行深度剖析，并对未来五年的发展趋势进行前瞻性预判。全景回顾：全球与中国BD交易的双向奔赴1.交易规模：中国领跑全球增长2025年，全球生物医药BD授权交易呈现出显著的回暖与扩张态势。此次交易总金额高达42.3亿美元，直接推动荣昌生物股价在两周内涨幅超105%。结 语2025年标志着中国创新药BD交易从“量变”走向“质变”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09995","06978","02615","BK1161"],"gpt_icon":0},{"id":"2601808383","title":"港股概念追踪|国家药监局优化临床急需境外已上市药品审评审批    创新药高景气度延续（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808383","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601808383?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:07","pubTimestamp":1767830855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，记者从国家药监局获悉，为加快临床急需境外已上市药品在境内上市，满足患者临床用药迫切需求，国家药监局进一步优化这类药品审评审批。公告显示，国家药监局将优化审评机制，加快审评速度;同时，也将完善检验制度，体现品种特点。据了解，2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU1794554557.SGD","IE00BPRC5H50.USD","09926","00013","LU2399975544.HKD","LU1720050803.USD","BK1587","LU2488822045.USD","159992","LU0348783233.USD","LU2476274308.USD","LU0417516738.SGD","LU0540923850.HKD","IE00B543WZ88.USD","LU0417516902.SGD","LU0348735423.USD","LU0417516571.SGD","LU0348766576.USD","LU0348784397.USD","06978","LU0348767384.USD","LU2778985437.USD","LU0348825331.USD","BK1191","BK1574","BK1161","LU0348827113.USD","LU1961090484.USD","BK1588","LU0561508036.HKD","LU2476274720.SGD","LU0634319403.HKD"],"gpt_icon":0},{"id":"2601382020","title":"久违大涨！创新药再度“起舞”，“出海”或成关键词","url":"https://stock-news.laohu8.com/highlight/detail?id=2601382020","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601382020?lang=zh_cn&edition=full","pubTime":"2026-01-08 07:17","pubTimestamp":1767827820,"startTime":"0","endTime":"0","summary":"　　步入2026年的3个交易日里，A股持续走强，在半导体、有色板块集体上涨的势头中，此前一度“沉寂”的创新药板块也再度亮眼，其中港股创新药板块更为出色；此外叠加“脑机接口”的风潮，有公募认为此前沉寂数年的医疗器械板块或也迎来投资机遇。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-01-08/doc-inhfpwux4039439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2601761808","title":"智通港股解盘 | 创新药填补资金空缺 管制引发国产替代走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2601761808","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601761808?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:45","pubTimestamp":1767789933,"startTime":"0","endTime":"0","summary":"1 月 6 日，中国商务部宣布加强对日本军民两用产品出口管制。知情人士透露，中国商务部相关部门正在评估该交易是否违反了中国的技术出口管制规定。隔夜美股光通信概念股Lumentum 大涨超 11%，Coherent 涨超 4%。2025年以来，动力电池行业因扩产潮导致供需失衡，部分企业为抢占市场份额低价倾销，专利纠纷亦频发，此次会议或为后续政策干预铺路。公司第三季营收 38.91 亿元，同比及环比分别升 16.27%及 11.46%，归母净利 1.74 亿元，同比跌 10.89%，环比升 20.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1592","SG9999003461.SGD","159992","06869","06978","BK1509","LU0307460666.USD","BK1594","BK1506","SG9999014674.SGD","BK1523","BK1149","BK1129","SG9999006597.SGD","BK1574","09696","BK1161","BK1190","LU0588546209.SGD"],"gpt_icon":1},{"id":"2601482765","title":"港股创新药板块尾盘持续拉升，荣昌生物涨超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601482765","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601482765?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:23","pubTimestamp":1767770639,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月7日，港股创新药板块尾盘持续拉升，荣昌生物涨超13%，泰格医药、凯莱英涨超9%，药明生物、信达生物涨超5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601073611419537.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611419537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","BK1574","LU2328871848.SGD","LU1969619763.USD","09995","688331","LU2488822045.USD","LU1064131003.USD","BK1161","159992","LU1064130708.USD","BK0239","06978","BK1583"],"gpt_icon":0},{"id":"2601876792","title":"凯莱英H股午后涨幅扩大 机构普遍看好创新药产业链的长期机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2601876792","media":"上证快讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601876792?lang=zh_cn&edition=full","pubTime":"2026-01-07 14:04","pubTimestamp":1767765869,"startTime":"0","endTime":"0","summary":"1月7日午后，凯莱英H股涨幅扩大，盘中一度涨至84.65港元/股。截至13时15分，凯莱英报83.05港元/股，涨7.37%，成交额约8265万港元。同时，凯莱英A股延续涨势。消息面上，多家机构看好创新药产业链长期机会。太平洋证券的研报显示，2026年创新药产业链景气度持续提升；海通证券研报显示，该机构看好创新药产业链长期机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107140609a4a65027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107140609a4a65027&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","06821","BK1161","BK1191","BK1574"],"gpt_icon":0},{"id":"2601748738","title":"2025年中国创新药十大出海，释放了哪些信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2601748738","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601748738?lang=zh_cn&edition=full","pubTime":"2026-01-07 14:00","pubTimestamp":1767765600,"startTime":"0","endTime":"0","summary":"2025年中国创新药出海规模质量双跃升，BD出海授权交易数量达157起，首付款合计70亿美元，交易总金额1356.55亿美元，均创历史新高。年度交易总额前十入围门槛超30亿美元，Newco、Co-Co等多元化合作模式占比上涨成新趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107141124a4a654bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107141124a4a654bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06978","LU2543165471.USD","BK1574","LU1023057109.AUD","BK1161","LU0359201612.USD","LU0359202008.SGD","01276","LU0359201885.HKD"],"gpt_icon":0},{"id":"2601760808","title":"港股创新药ETF基金涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601760808","media":"云掌财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601760808?lang=zh_cn&edition=full","pubTime":"2026-01-07 13:58","pubTimestamp":1767765495,"startTime":"0","endTime":"0","summary":"盘面上，港股创新药表现活跃，凯莱英飙涨7%，泰格医药、昭衍新药、康方生物涨超5%，和黄医药、翰森制药、恒瑞医药等个股涨超4%。截至10：34，热门ETF——港股创新药ETF基金上涨2.85%，冲击三连涨！数据显示，港股创新药ETF基金近60日“吸金”超1亿；最新基金规模达9.39亿元。港股创新药ETF基金跟踪中证港股通创新药指数，指数编制方式更科学合理，成分股涵盖如百济神州、信达生物和药明生物等领军企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107135820a4a649a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107135820a4a649a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06821","BK1191","02269","09926","01801","01276","02315","06127","00013","BK1574","03692","06978"],"gpt_icon":0},{"id":"2601825895","title":"罕见病创新药内地首张处方药开出 港股通创新药ETF板块迎双重驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2601825895","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601825895?lang=zh_cn&edition=full","pubTime":"2026-01-07 11:27","pubTimestamp":1767756474,"startTime":"0","endTime":"0","summary":"近日，罕见病创新药司拉德帕在中国内地开出了首张处方。创新药物将走入更多寻常百姓家。1月7日，盘中港股创新药持续走强。港股通创新药ETF嘉实盘中涨超3%。2026年我国医药生物行业将正式步入创新药大时代，创新药将逐渐占据我国医药生物行业的主导地位，医保商保的互补结合将长期打开支付空间的天花板，创新药将持续蓬勃发展。创新药产业链行业，受益于创新药的快速发展预计仍将保持良好增长势头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107112826a6fcca5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107112826a6fcca5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","09926","BK1141","03347","BK1161","02157","BK1576","01530","06978","BK1574"],"gpt_icon":0},{"id":"2601933828","title":"创新药板块持续活跃，益诺思触及20cm涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2601933828","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601933828?lang=zh_cn&edition=full","pubTime":"2026-01-07 10:40","pubTimestamp":1767753640,"startTime":"0","endTime":"0","summary":"1月7日，创新药板块持续活跃，截至发稿，益诺思触及20 cm涨停，报55.31元，换手率5.12%，成交额2.45亿元。据行业数据显示，2025年中国创新药产业出海授权交易总额突破1300亿美元，上市新药数量达76个，双双创下历史新高。业内分析认为，在创新药研发需求持续扩张、安评环节壁垒凸显的多种逻辑支撑下，具备GLP实验室资质及项目经验积淀的头部安评企业，有望迎来收入与盈利能力同步提升的双重拐点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026010700010559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","BK0216","688710","BK1574","BK1161"],"gpt_icon":0},{"id":"2601884779","title":"港股异动 | 轩竹生物-B(02575)早盘涨超6% 创新药吡洛西利2026元旦医保落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884779","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601884779?lang=zh_cn&edition=full","pubTime":"2026-01-07 09:55","pubTimestamp":1767750903,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B早盘涨超6%，截至发稿，涨2.36%，报52.05港元，成交额299.05万港元。消息面上，2026年1月1日，吡洛西利国家医保正式执行！2025年12月7日，国家医疗保障局公布2025年国家医保药品目录调整结果，轩竹生物自主研发的1类创新药、CDK4/6抑制剂吡洛西利片成功纳入目录，为晚期乳腺癌患者带来医保报销新福利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159992","06978","02575","BK1191","BK1161"],"gpt_icon":0},{"id":"2601426698","title":"晶泰科技孵化企业ReviR溪砾科技实现罕见病首创新药突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2601426698","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601426698?lang=zh_cn&edition=full","pubTime":"2026-01-07 09:08","pubTimestamp":1767748117,"startTime":"0","endTime":"0","summary":"【晶泰科技孵化企业ReviR溪砾科技实现罕见病首创新药突破】近日，晶泰科技孵化企业ReviR溪砾科技获得国家药监局核准签发关于小分子管线RTX-117用于治疗腓骨肌萎缩症（CMT）的《药物临床试验批准通知书》，将按计划于2026年第一季度开启I期临床试验。RTX-117是国内首款针对CMT的1类创新药管线，也是ReviR与晶泰科技深度合作、借助AI+机器人辅助研发的一系列罕见病药物管线中首个进入临床的项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202601073610959712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02228","BK1574","159992","06978","BK1161","BK1617","BK1141"],"gpt_icon":0},{"id":"2601093867","title":"筑巢引凤聚合力 创新药出海再添“浦东动力”","url":"https://stock-news.laohu8.com/highlight/detail?id=2601093867","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601093867?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:33","pubTimestamp":1767688426,"startTime":"0","endTime":"0","summary":"当前我国创新药产业正迎来历史性转折——历经多年在研发、监管、资本与供应链上的厚积薄发，行业正实现从“快速追随者”向“源头首创者”的进阶跨越。这背后有着扎实的数据与市场表现支撑：当前中国医药产业规模已位居全球第二，创新药在研数目约占全球的30%；2025年我国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，均创历史新高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://biz.eastmoney.com/a/202601063610199490.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://biz.eastmoney.com/a/202601063610199490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","BK1161","06978"],"gpt_icon":0},{"id":"2601135648","title":"有成熟出海能力的药企，长期增长更有保障","url":"https://stock-news.laohu8.com/highlight/detail?id=2601135648","media":"明大教主","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601135648?lang=zh_cn&edition=full","pubTime":"2026-01-06 14:51","pubTimestamp":1767682313,"startTime":"0","endTime":"0","summary":"尤其是百奥赛图，我原以为百奥A股发行后筹码压力增强，可能会带来H股情绪抛压，百奥H股怎么不得回撤一波？现我国在研创新药管线约占全球30%，位列全球第二，百奥赛图的模型动物和临床前CRO业务必然会受益，抗体开发业务间接受益。另外百奥也是最早实现模型动物“反向出海”的国内企业，海外MNC认可度最高。相比于一些只能在国内靠集采、国谈或是价格内卷占份额获益的企业，我还是更看重赚外汇能力成熟、成长性确定的百奥赛图。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106150109a6f91e9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106150109a6f91e9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","LU1969619763.USD","BK1583","06160","LU1251922891.USD","LU1770034418.SGD","BK1500","LU0307460666.USD","06978","BK1574","LU0588546209.SGD","BK1161","LU1303224171.USD","LU2328871848.SGD","LU1719994722.HKD"],"gpt_icon":0},{"id":"2601868644","title":"中信建投：脑机接口有望打开万亿市场空间 需发掘国家政策支持和具有真实需求“真脑机”","url":"https://stock-news.laohu8.com/highlight/detail?id=2601868644","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601868644?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:27","pubTimestamp":1767670058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，脑机接口升级为十五五产业战略，多重政策强力支持下，产业落地有望提速，建议重视投资机遇。脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来看若能实现增强人、并与AI和机器人融合，有望打开万亿市场空间。在投资方向选择方面，非侵入式和侵入式脑机接口无优劣之分，但需发掘国家政策支持和具有真实需求的“真脑机”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2125910500.SGD","BK1574","BK1141","LU2242644610.SGD","01177","06160","BK1161","LU0708995583.HKD","02269","BK1583","LU0052750758.USD","09926","01099","SHPMY","00013","02359","02607","01801","BK1576","LU0320764599.SGD","06978","03347","LU1046422090.SGD","LU2045819591.USD"],"gpt_icon":0},{"id":"2601189294","title":"科伦博泰ITGB6靶向ADC癌症新药获批临床|复宏汉霖三款创新药IND同期获受理|和黄医药赛沃替尼申报上市并获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2601189294","media":"中国医药创新促...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601189294?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:24","pubTimestamp":1767669859,"startTime":"0","endTime":"0","summary":"12月30日，和黄医药宣布，赛沃替尼用于经过至少2种治疗后失败的MET基因扩增的局部晚期或转移性胃癌或胃食道连接部腺癌成人患者的新药上市申请已获中国国家药品监督管理局受理，并获纳入优先审评。以上三款产品皆拟用于实体肿瘤的治疗。科伦博泰 注射用SKB1051月4日，中国国家药监局药品审评中心官网最新公示，科伦博泰申报的1类新药注射用SKB105获批临床，拟开发治疗晚期实体瘤。公开资料显示，这是一款靶向整合素β6的抗体偶联药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106121530a4a199b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106121530a4a199b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1574","00013","02696","06978","BK1588","BK1587","BK1191","BK1161"],"gpt_icon":0},{"id":"2601098897","title":"恒瑞医药、远大医药等创新药密集突破，将重塑前列腺癌诊疗格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2601098897","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601098897?lang=zh_cn&edition=full","pubTime":"2026-01-06 10:37","pubTimestamp":1767667064,"startTime":"0","endTime":"0","summary":"前列腺癌已成为威胁全球男性健康的主要恶性肿瘤之一，在我国的发病率亦呈持续攀升态势。据数据显示，2022年中国前列腺癌新发病例数约达13.42万人，药物需求迫切。近期，恒瑞医药、远大医药等国内药企相继在前列腺癌领域传来研发进展，为国内患者带来新的治疗希望。本次临床试验的批准标志着恒瑞医药在前列腺癌治疗领域的产品管线布局取得重要进展。在前列腺癌诊断领域，远大医药的创新放射性核素偶联药物取得关键突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106104202a4a14741&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106104202a4a14741&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","01276","BK1161","BK1574","LU2543165471.USD","BK1191","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0546},{"period":"1month","weight":-0.0382},{"period":"3month","weight":-0.4069},{"period":"6month","weight":-0.2284},{"period":"1year","weight":0.1787},{"period":"ytd","weight":-0.0546}],"compareEarnings":[{"period":"1week","weight":0.0202},{"period":"1month","weight":0.0281},{"period":"3month","weight":-0.0054},{"period":"6month","weight":0.0833},{"period":"1year","weight":0.3563},{"period":"ytd","weight":0.0202}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括EAL和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.063839},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}